EPIDAREX IS A TRANSATLANTIC VENTURE CAPITAL FIRM LED BY A DIVERSE TEAM OF EARLY-STAGE INVESTORS BUILDING BREAKTHROUGH LIFE SCIENCE COMPANIES IN EMERGING HUBS
We are trusted partners to our founders and co-investors. We use our deep scientific and industry networks to create exceptional value and shared success.
Epidarex builds the extraordinary.
Recent News
Apellis Present Pivotal VALIANT Results at Kidney Week Highlighting Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN
WALTHAM, Mass. October 26, 2024 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® today announced that positive results from the Phase
Dr. Falk Pharma acquires spinout Kynos Therapeutics to develop its novel KMO inhibitors for acute pancreatitis
29 October 2024, Dr. Falk Pharma GmbH today announced completion of the acquisition of Kynos Therapeutics Ltd., a clinical stage biopharmaceutical company focusing